New BPCIA Litigations Regarding Celltrion’s Trastuzumab and Rituximab Biosimilars

On January 11, 2018, Celltrion and Teva filed two lawsuits against Genentech in the District Court for the Northern District of California.  Case No. 3:18-cv-00274 relates to Celltrion’s Herzuma®, its trastuzumab biosimilar. According to the complaint, Celltrion and Teva seek a declaratory judgment of non-infringement, invalidity, and/or unenforceability of 38 patents. Case No. 3:18-cv-00276 relates to Celltrion’s Truxima®, its rituximab biosimilar. According to the complaint, Celltrion and Teva seek a declaratory judgment of non-infringement and invalidity of 37 patents.

On January 12, 2018, Genentech filed its own lawsuits against Celltrion and Teva. Case No. 1-18-cv-00095, filed in the District Court for the District of Delaware, relates to Celltrion’s Herzuma® product.  According to the Delaware complaint, Genentech seeks a judgment of infringement of 40 patents. Case No. 1:18-cv-000-574, filed in the District Court for the District of New Jersey, relates to Celltrion’s Truxima® product. According to the New Jersey complaint, Genentech seeks a judgment of infringement of 40 patents.

Download PDF